Life Sciences Research for Lifelong Health

Megan Cassidy

Megan Cassidy completed her BSc in Biology at the University of Bath. During her degree she spent a placement year at Astex Pharmaceuticals in Cambridge investigating the effect of activating MEK mutations on resistance to ERK pathway inhibitors.

This prompted her interest in signalling pathways and she joined Simon’s lab at the Babraham Institiute in 2017 as a Research Assistant working on a collaboration with Phoremost to develop a novel tools to identify ERK pathway inhibitors. Having found the Cook lab to her liking she decided to stay and Simon found no particular reason to object so she started her PhD in Oct 2018.

Outside of work Megan enjoys various sports (including cycling and swimming), playing her instruments (oboe and guitar, not at the same time) and cuddling her cat (yes, really!)

 

Latest Publications

Control of cell death and mitochondrial fission by ERK1/2 MAP Kinase signalling.

Cook SJ, Stuart K, Gilley R

The FEBS journal
1742-4658: (2017)

PMID: 28548464

Visualisation of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.

Sipthorp J, Lebraud H, Gilley R

Bioconjugate chemistry
1520-4812: (2017)

PMID: 28449575

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Galloway A, Saveliev A, Łukasiak S

Science (New York, N.Y.)
352 1095-9203:453-9 (2016)

PMID: 27102483

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ

Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)

PMID: 26959608

Maternal DNA Methylation Regulates Early Trophoblast Development.

Branco MR, King M, Perez-Garcia V

Developmental cell
36 1878-1551:152-63 (2016)

PMID: 26812015

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.

Caunt CJ, Sale MJ, Smith PD

Nature reviews. Cancer
15 1474-1768:577-92 (2015)

PMID: 26399658

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M

Cellular and molecular life sciences : CMLS
1420-9071: (2015)

PMID: 26346493